Compare Stocks

Date Range: 

 SynlogicLipocineGalectin TherapeuticsLiminal BioSciencesHepion Pharmaceuticals
SymbolNASDAQ:SYBXNASDAQ:LPCNNASDAQ:GALTNASDAQ:LMNLNASDAQ:HEPA
Price Information
Current Price$3.14$1.39$4.00$4.79$1.60
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.61.41.41.11.1
Analysis Score3.43.53.53.10.0
Community Score2.72.82.71.82.8
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.80.01.7
Earnings & Valuation Score1.30.60.00.61.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$13.25$3.00$14.00$18.00$80.00
% Upside from Price Target321.97% upside115.83% upside250.00% upside275.78% upside4,900.00% upside
Trade Information
Market Cap$128.27 million$122.72 million$228.62 million$143.43 million$121.96 million
Beta2.20.752.041.871.47
Average Volume908,9403,943,1501,933,236728,8014,965,481
Sales & Book Value
Annual Revenue$2.22 million$170,000.00N/A$3.70 millionN/A
Price / Sales57.78721.91N/A38.77N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.86 per share$0.25 per share$0.76 per share$3.06 per share$4.19 per share
Price / Book0.655.56N/A1.57N/A
Profitability
Net Income$-51,370,000.00$-13,010,000.00$-13,290,000.00$-155,020,000.00$-6,720,000.00
EPS($1.70)($0.50)($0.39)($10.94)($5.95)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,761.83%N/AN/A-2,758.32%N/A
Return on Equity (ROE)-41.64%-195.34%-56.13%-196.39%-116.73%
Return on Assets (ROA)-34.39%-88.86%-49.42%-88.62%-78.47%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.22%N/A2.42%0.02%
Current Ratio16.42%4.27%13.62%2.17%3.63%
Quick Ratio16.42%4.27%13.62%1.75%3.63%
Ownership Information
Institutional Ownership Percentage39.53%10.87%17.58%13.45%2.97%
Insider Ownership Percentage17.95%10.50%40.70%N/A0.10%
Miscellaneous
Employees7211625113
Shares Outstanding40.85 million88.29 million57.16 million29.94 million76.23 million
Next Earnings Date5/13/2021 (Confirmed)8/5/2021 (Estimated)5/10/2021 (Estimated)5/12/2021 (Estimated)7/5/2021 (Estimated)
OptionableNot OptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
-$0.20 Earnings Per Share Expected for Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) This Quarter-$0.20 Earnings Per Share Expected for Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) This Quarter
americanbankingnews.com - May 7 at 1:36 AM
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’
apnews.com - May 6 at 8:20 AM
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a AMBITION Clinical Trial of CRV431 for the Treatment of Advanced NASHHepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
finance.yahoo.com - May 6 at 8:20 AM
Weak fundamental momentum pushes Hepion Pharmaceuticals Inc. (HEPA) lowerWeak fundamental momentum pushes Hepion Pharmaceuticals Inc. (HEPA) lower
marketingsentinel.com - May 5 at 12:17 PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Decline in Short InterestHepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Decline in Short Interest
americanbankingnews.com - May 2 at 6:42 AM
Hepion Pharmaceuticals Presents Machine Learning "Learn and Confirm" Modeling Strategy at 4th Global NASH CongressHepion Pharmaceuticals Presents Machine Learning "Learn and Confirm" Modeling Strategy at 4th Global NASH Congress
benzinga.com - May 1 at 9:19 AM
Hepion Pharmaceuticals Inc (HEPA)Hepion Pharmaceuticals Inc (HEPA)
investing.com - April 30 at 2:01 PM
After A 5.95% Rise In The Last Week, Does Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Still Make Sense To Buy?After A 5.95% Rise In The Last Week, Does Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Still Make Sense To Buy?
marketingsentinel.com - April 30 at 1:21 PM
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th ...Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th ...
apnews.com - April 29 at 10:14 AM
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH CongressHepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
finance.yahoo.com - April 29 at 10:14 AM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA): A Disaster In The Making Or A Gold Mine?Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA): A Disaster In The Making Or A Gold Mine?
marketingsentinel.com - April 27 at 2:45 PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Jumps 2.98% in Recent Session, Here’s Everything You Need To KnowHepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Jumps 2.98% in Recent Session, Here’s Everything You Need To Know
stocksregister.com - April 26 at 8:24 AM
Here’s Why Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is an Attractive Pick for Investors NowHere’s Why Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is an Attractive Pick for Investors Now
stocksregister.com - April 21 at 12:31 PM
 Analysts Expect Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Will Post Earnings of -$0.20 Per Share Analysts Expect Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Will Post Earnings of -$0.20 Per Share
americanbankingnews.com - April 19 at 6:36 PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Expected to Announce Earnings of -$0.20 Per ShareHepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Expected to Announce Earnings of -$0.20 Per Share
americanbankingnews.com - April 19 at 6:36 PM
Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Rises By 57.6%Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Rises By 57.6%
americanbankingnews.com - April 17 at 3:06 AM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Share Price Tumble Recently, But Trouble May Still Be AfootHepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Share Price Tumble Recently, But Trouble May Still Be Afoot
stocksregister.com - April 13 at 10:18 AM
Small Cap Stock Hepion Pharmaceuticals, Inc. (HEPA) is a Buy – AnalystsSmall Cap Stock Hepion Pharmaceuticals, Inc. (HEPA) is a Buy – Analysts
marketingsentinel.com - April 12 at 1:07 PM
Nobel Laureate Dr. Michael Houghton joins API Scientific Advisory BoardNobel Laureate Dr. Michael Houghton joins API Scientific Advisory Board
markets.businessinsider.com - March 30 at 7:09 PM
Market Analysts see Hepion Pharmaceuticals Inc. [HEPA] gaining to $14. Time to buy?Market Analysts see Hepion Pharmaceuticals Inc. [HEPA] gaining to $14. Time to buy?
dbtnews.com - March 29 at 1:01 PM
ENDRA Life Sciences Inc.: ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business UpdateENDRA Life Sciences Inc.: ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update
finanznachrichten.de - March 25 at 6:47 PM
Brookline Capital Markets Sticks to Their Buy Rating for Hepion Pharmaceuticals (HEPA)Brookline Capital Markets Sticks to Their Buy Rating for Hepion Pharmaceuticals (HEPA)
smarteranalyst.com - March 23 at 8:44 PM
Hepion Pharmaceuticals Lead Drug Shows Antifibrotic Effects In Animal StudiesHepion Pharmaceutical's Lead Drug Shows Antifibrotic Effects In Animal Studies
benzinga.com - March 23 at 1:42 PM
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic ...DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic ...
apnews.com - March 23 at 8:01 AM
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceuticals Lead Drug, CRV431DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's Lead Drug, CRV431
benzinga.com - March 23 at 8:01 AM
DateCompanyBrokerageAction
3/25/2021SynlogicSVB LeerinkBoost Price Target
3/24/2021SynlogicJonestradingInitiated Coverage
1/13/2021SynlogicChardan CapitalBoost Price Target
8/10/2020SynlogicHC WainwrightReiterated Rating
5/10/2020SynlogicOppenheimerReiterated Rating
11/13/2019SynlogicPiper Jaffray CompaniesReiterated Rating
8/21/2019SynlogicCitigroupDowngrade
8/9/2019SynlogicWedbushReiterated Rating
12/10/2020LipocineLADENBURG THALM/SH SHUpgrade
8/10/2018LipocineCanaccord GenuityReiterated Rating
4/3/2020Galectin TherapeuticsB. RileyReiterated Rating
3/26/2021Liminal BioSciencesLeede Jones GabReiterated Rating
1/29/2021Liminal BioSciencesBloom BurtonDowngrade
12/21/2020Liminal BioSciencesPiper SandlerInitiated Coverage
8/11/2020Liminal BioSciencesEchelon Wealth PartnersReiterated Rating
12/1/2020Hepion PharmaceuticalsRoth CapitalBoost Price Target
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.